Alkem Laboratories Limited (ALKEM.BO)
- Previous Close
5,221.00 - Open
5,222.00 - Bid 5,315.00 x --
- Ask 5,344.75 x --
- Day's Range
5,194.45 - 5,396.80 - 52 Week Range
4,409.90 - 6,440.00 - Volume
6,490 - Avg. Volume
1,771 - Market Cap (intraday)
636.319B - Beta (5Y Monthly) 0.43
- PE Ratio (TTM)
29.55 - EPS (TTM)
180.12 - Earnings Date May 29, 2025
- Forward Dividend & Yield 42.00 (0.80%)
- Ex-Dividend Date Feb 14, 2025
- 1y Target Est
5,365.71
Alkem Laboratories Limited, a pharmaceutical company, engages in the research and development, manufacture, and sale of pharmaceutical and nutraceutical products in India, the United States, and internationally. The company offers branded generics, generic drugs, active pharmaceutical ingredients, and biosimilars, and nutraceuticals in acute and chronic therapeutic areas comprising anti-infective, gastro-intestinal, pain/analgesic, anti-diabetic, neuro/central nervous system, gynecology, respiratory, dermatology, and cardiac diseases. It also provides vitamins, minerals, and nutrients, as well as mouth wash, shampoos, pregnancy detection kits, and condoms. The company was incorporated in 1973 and is headquartered in Mumbai, India.
www.alkemlabs.com17,432
Full Time Employees
March 31
Fiscal Year Ends
Sector
Recent News: ALKEM.BO
View MorePerformance Overview: ALKEM.BO
Trailing total returns as of 5/19/2025, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ALKEM.BO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ALKEM.BO
View MoreValuation Measures
Market Cap
624.25B
Enterprise Value
591.63B
Trailing P/E
28.99
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
4.98
Price/Book (mrq)
5.43
Enterprise Value/Revenue
4.72
Enterprise Value/EBITDA
20.20
Financial Highlights
Profitability and Income Statement
Profit Margin
16.88%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
127.57B
Net Income Avi to Common (ttm)
21.53B
Diluted EPS (ttm)
180.12
Balance Sheet and Cash Flow
Total Cash (mrq)
22.89B
Total Debt/Equity (mrq)
12.41%
Levered Free Cash Flow (ttm)
--